Prospective Grant of Exclusive Patent License: Development and Commercialization of Nitrite Salts for the Treatment, Amelioration, and Prevention by Any Route of Administration of Pulmonary Hypertension, Including All WHO Classifications of Pulmonary Hypertension, e.g., Groups 1-5, 96023 [2016-31437]

Download as PDF Federal Register / Vol. 81, No. 250 / Thursday, December 29, 2016 / Notices asabaliauskas on DSK3SPTVN1PROD with NOTICES Date: February 13, 2017. Time: 12:01 p.m. to 5:00 p.m. Agenda: To review and evaluate grant applications. Place: National Institute on Aging, Gateway Building, Suite 2W200, 7201 Wisconsin Ave., Bethesda, MD 20892. Contact Person: Maurizio Grimaldi, MD, Ph.D., Scientific Review Officer, National Institute on Aging, National Institutes of Health, 7201 Wisconsin Avenue, Room 2C218, Bethesda, MD 20892, 301–496–9374, grimaldim2@mail.nih.gov. Name of Committee: National Institute on Aging Special Emphasis Panel; 2017 Beeson Review. Date: February 24, 2017. Time: 11:00 a.m. to 3:30 p.m. Agenda: To review and evaluate grant applications. Place: National Institute on Aging, Gateway Building, Suite 2W200, 7201 Wisconsin Avenue, Bethesda, MD 20892 (Telephone Conference Call). Contact Person: Alexander Parsadanian, Ph.D., Scientific Review Officer, National Institute on Aging, Gateway Building 2C/212, 7201 Wisconsin Avenue, Bethesda, MD 20892, 301–496–9666, Parsadaniana@ nia.nih.gov. (Catalogue of Federal Domestic Assistance Program Nos. 93.866, Aging Research, National Institutes of Health, HHS) and incorporated under the laws of Delaware. DATES: Only written comments and/or applications for a license which are received by the NHLBI Office of Technology Transfer and Development on or before January 13, 2017 will be considered. ADDRESSES: Requests for copies of the patent application, inquiries, and comments relating to the contemplated exclusive license should be directed to: Cristina Thalhammer-Reyero, Ph.D., MBA, Senior Licensing and Patenting Manager, NHLBI Office of Technology Transfer and Development, 31 Center Drive Room 4A29, MSC2479, Bethesda, MD 20892–2479; Telephone: +1–301– 435–4507; Fax: +1–301–594–3080; Email: thalhamc@mail.nih.gov. SUPPLEMENTARY INFORMATION: The following represents the intellectual property to be licensed under the prospective agreement: PCT Application Number: PCT/ US2004/21985, filed 9 July 2004, and corresponding US, EP, CA, AU and JP filings; and PCT Patent Application PCT/US2004/22232 filed 9 July 2004, and corresponding issued patents in EP, Dated: December 23, 2016. CA, AU and JP, as well as US 8,927,030 Melanie J. Pantoja, issued 01/06/2015; US 9,387,224 issued Program Analyst, Office of Federal Advisory 07/12/2016, and two pending US patent Committee Policy. applications; Titled ‘‘Use of Nitrite Salts [FR Doc. 2016–31566 Filed 12–28–16; 8:45 am] for the treatment of Cardiovascular BILLING CODE 4140–01–P Conditions’’ (NIH Reference No. E–254– 2003/0,1,2,3) With respect to persons who have an DEPARTMENT OF HEALTH AND obligation to assign their right, title and HUMAN SERVICES interest to the Government of the United States of America, the patent rights in National Institutes of Health these inventions have been assigned to the Government of the United States of Prospective Grant of Exclusive Patent America. License: Development and The prospective exclusive license Commercialization of Nitrite Salts for territory may be worldwide and the the Treatment, Amelioration, and field of use may be limited to: ‘‘Use of Prevention by Any Route of the Licensed Patent Rights for the Administration of Pulmonary treatment, amelioration, and prevention Hypertension, Including All WHO of any kind or nature and by any route Classifications of Pulmonary of administration of Pulmonary Hypertension, e.g., Groups 1–5 Hypertension, including all WHO classifications of pulmonary AGENCY: National Institutes of Health, hypertension, e.g., Groups 1–5’’. HHS. The invention pertains to the ACTION: Notice. unexpected finding that low, SUMMARY: The National Heart, Lung, and physiological and non-toxic Blood Institute (‘‘NHLBI’’), an institute concentrations of sodium nitrite are able of the National Institutes of Health; an to increase blood flow and produce agency within the Department of Health vasodilation by infused and nebulized and Human Services, is contemplating routes of administration. This notice is made in accordance the grant of an exclusive patent license with 35 U.S.C. 209 and 37 CFR part 404. to commercialize the invention(s) The prospective Exclusive Patent embodied in the intellectual property License will be royalty bearing and may estate stated in the Summary be granted unless within fifteen (15) Information section of this notice to days from the date of this published United Therapeutics Corporation (‘‘United’’) located in Silver Spring, MD notice, the NHLBI Office of Technology VerDate Sep<11>2014 18:41 Dec 28, 2016 Jkt 241001 PO 00000 Frm 00068 Fmt 4703 Sfmt 4703 96023 Transfer and Development receives written evidence and argument that establishes that the grant of the license would not be consistent with the requirements of 35 U.S.C. 209 and 37 CFR part 404. Complete applications for a license in the prospective field of use that are timely filed in response to this notice will be treated as objections to the grant of the contemplated Exclusive Patent License. Comments and objections to this notice submitted will not be made available for public inspection and, to the extent permitted by law, will not be released under the Freedom of Information Act, 5 U.S.C. 552. Dated: December 21, 2016. Cristina Thalhammer-Reyero, Senior Licensing and Patenting Manager, Office of Technology Transfer and Development, National Heart, Lung, and Blood Institute. [FR Doc. 2016–31437 Filed 12–28–16; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Center for Complementary and Integrative Health; Notice of Meeting Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of a meeting of the National Advisory Council for Complementary and Integrative Health. The meeting will be open to the public as indicated below, with attendance limited to space available. Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should notify the Contact Person listed below in advance of the meeting. The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: National Advisory Council for Complementary and Integrative Health. Date: February 3, 2017. Closed: 8:30 a.m. to 9:15 a.m. E:\FR\FM\29DEN1.SGM 29DEN1

Agencies

[Federal Register Volume 81, Number 250 (Thursday, December 29, 2016)]
[Notices]
[Page 96023]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2016-31437]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Prospective Grant of Exclusive Patent License: Development and 
Commercialization of Nitrite Salts for the Treatment, Amelioration, and 
Prevention by Any Route of Administration of Pulmonary Hypertension, 
Including All WHO Classifications of Pulmonary Hypertension, e.g., 
Groups 1-5

AGENCY: National Institutes of Health, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The National Heart, Lung, and Blood Institute (``NHLBI''), an 
institute of the National Institutes of Health; an agency within the 
Department of Health and Human Services, is contemplating the grant of 
an exclusive patent license to commercialize the invention(s) embodied 
in the intellectual property estate stated in the Summary Information 
section of this notice to United Therapeutics Corporation (``United'') 
located in Silver Spring, MD and incorporated under the laws of 
Delaware.

DATES: Only written comments and/or applications for a license which 
are received by the NHLBI Office of Technology Transfer and Development 
on or before January 13, 2017 will be considered.

ADDRESSES: Requests for copies of the patent application, inquiries, 
and comments relating to the contemplated exclusive license should be 
directed to: Cristina Thalhammer-Reyero, Ph.D., MBA, Senior Licensing 
and Patenting Manager, NHLBI Office of Technology Transfer and 
Development, 31 Center Drive Room 4A29, MSC2479, Bethesda, MD 20892-
2479; Telephone: +1-301-435-4507; Fax: +1-301-594-3080; Email: 
thalhamc@mail.nih.gov.

SUPPLEMENTARY INFORMATION: The following represents the intellectual 
property to be licensed under the prospective agreement:
    PCT Application Number: PCT/US2004/21985, filed 9 July 2004, and 
corresponding US, EP, CA, AU and JP filings; and PCT Patent Application 
PCT/US2004/22232 filed 9 July 2004, and corresponding issued patents in 
EP, CA, AU and JP, as well as US 8,927,030 issued 01/06/2015; US 
9,387,224 issued 07/12/2016, and two pending US patent applications; 
Titled ``Use of Nitrite Salts for the treatment of Cardiovascular 
Conditions'' (NIH Reference No. E-254-2003/0,1,2,3)
    With respect to persons who have an obligation to assign their 
right, title and interest to the Government of the United States of 
America, the patent rights in these inventions have been assigned to 
the Government of the United States of America.
    The prospective exclusive license territory may be worldwide and 
the field of use may be limited to: ``Use of the Licensed Patent Rights 
for the treatment, amelioration, and prevention of any kind or nature 
and by any route of administration of Pulmonary Hypertension, including 
all WHO classifications of pulmonary hypertension, e.g., Groups 1-5''.
    The invention pertains to the unexpected finding that low, 
physiological and non-toxic concentrations of sodium nitrite are able 
to increase blood flow and produce vasodilation by infused and 
nebulized routes of administration.
    This notice is made in accordance with 35 U.S.C. 209 and 37 CFR 
part 404. The prospective Exclusive Patent License will be royalty 
bearing and may be granted unless within fifteen (15) days from the 
date of this published notice, the NHLBI Office of Technology Transfer 
and Development receives written evidence and argument that establishes 
that the grant of the license would not be consistent with the 
requirements of 35 U.S.C. 209 and 37 CFR part 404.
    Complete applications for a license in the prospective field of use 
that are timely filed in response to this notice will be treated as 
objections to the grant of the contemplated Exclusive Patent License. 
Comments and objections to this notice submitted will not be made 
available for public inspection and, to the extent permitted by law, 
will not be released under the Freedom of Information Act, 5 U.S.C. 
552.

    Dated: December 21, 2016.
Cristina Thalhammer-Reyero,
Senior Licensing and Patenting Manager, Office of Technology Transfer 
and Development, National Heart, Lung, and Blood Institute.
[FR Doc. 2016-31437 Filed 12-28-16; 8:45 am]
 BILLING CODE 4140-01-P